180 related articles for article (PubMed ID: 10533617)
1. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model.
Wilson DP; Saward L; Zahradka P; Cheung PK
Cardiovasc Res; 1999 Jun; 42(3):761-72. PubMed ID: 10533617
[TBL] [Abstract][Full Text] [Related]
2. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis.
Huckle WR; Drag MD; Acker WR; Powers M; McFall RC; Holder DJ; Fujita T; Stabilito II; Kim D; Ondeyka DL; Mantlo NB; Chang RS; Reilly CF; Schwartz RS; Greenlee WJ; Johnson RG
Circulation; 1996 Mar; 93(5):1009-19. PubMed ID: 8598064
[TBL] [Abstract][Full Text] [Related]
3. Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.
Parlakpinar H; Ozer MK; Acet A
Cytokine; 2011 Dec; 56(3):688-94. PubMed ID: 21975128
[TBL] [Abstract][Full Text] [Related]
4. Topical application of AT1 receptor antagonists prevents medial and neointimal proliferation after balloon injury.
Taguchi J; Abe J; Ohno M; Schwartz SM; Kurokawa K
Blood Press Suppl; 1994; 5():38-42. PubMed ID: 7889199
[TBL] [Abstract][Full Text] [Related]
5. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Lynch JJ; Stump GL; Wallace AA; Painter CA; Thomas JM; Kusma SE; Gould RJ; Grossman W
J Am Coll Cardiol; 1999 Sep; 34(3):876-84. PubMed ID: 10483973
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model.
Huber KC; Schwartz RS; Edwards WD; Camrud AR; Bailey KR; Jorgenson MA; Holmes DR
Am Heart J; 1993 Mar; 125(3):695-701. PubMed ID: 8382444
[TBL] [Abstract][Full Text] [Related]
8. Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.
Burke SE; Lubbers NL; Gagne GD; Wessale JL; Dayton BD; Wegner CD; Opgenorth TJ
J Cardiovasc Pharmacol; 1997 Jul; 30(1):33-41. PubMed ID: 9268219
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.
Stoll M; Steckelings UM; Paul M; Bottari SP; Metzger R; Unger T
J Clin Invest; 1995 Feb; 95(2):651-7. PubMed ID: 7860748
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
11. [Vascular remodeling and angiotensin II].
Takemoto M; Egashira K
Nihon Rinsho; 1999 May; 57(5):1158-63. PubMed ID: 10361450
[TBL] [Abstract][Full Text] [Related]
12. Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade.
Hafizi S; Chester AH; Allen SP; Morgan K; Yacoub MH
Coron Artery Dis; 1998; 9(4):167-75. PubMed ID: 9649922
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury.
Prescott MF; Webb RL; Reidy MA
Am J Pathol; 1991 Dec; 139(6):1291-6. PubMed ID: 1750504
[TBL] [Abstract][Full Text] [Related]
14. Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury.
Moon MC; Molnar K; Yau L; Zahradka P
J Vasc Surg; 2004 Jul; 40(1):130-7. PubMed ID: 15218473
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibitors or DuP753 prevent neointimal formation following balloon injury with single topical or multiple systemic application.
Taguchi J; Abe J; Okazaki H; Ochiai M; Ohno M; Takuwa Y; Kurokawa K
Biochem Biophys Res Commun; 1993 Oct; 196(2):969-74. PubMed ID: 8240375
[TBL] [Abstract][Full Text] [Related]
16. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.
Herbert JM; Delisée C; Dol F; Schaeffer P; Cazaubon C; Nisato D; Chatelain P
Eur J Pharmacol; 1994 Jan; 251(2-3):143-50. PubMed ID: 8149971
[TBL] [Abstract][Full Text] [Related]
17. Effect of angiotensin II receptor blockade on the interaction between enalaprilat and doxazosin in rat tail arteries.
Marwood JF
Clin Exp Pharmacol Physiol; 1998; 25(7-8):517-21. PubMed ID: 9673422
[TBL] [Abstract][Full Text] [Related]
18. Survival after myocardial infarction in rats: captopril versus losartan.
Milavetz JJ; Raya TE; Johnson CS; Morkin E; Goldman S
J Am Coll Cardiol; 1996 Mar; 27(3):714-9. PubMed ID: 8606287
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure.
Uhlenius N; Miettinen A; Vuolteenaho O; Tikkanen I
Kidney Blood Press Res; 2002; 25(2):71-9. PubMed ID: 12077487
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells.
Zahradka P; Werner JP; Buhay S; Litchie B; Helwer G; Thomas S
J Mol Cell Cardiol; 2002 Dec; 34(12):1609-21. PubMed ID: 12505059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
